Scarica l'app Stockscreener
8.41
1.20%
0.10
Pre-mercato:
8.27
-0.14
-1.66%
Precedente Chiudi:
$8.31
Aprire:
$8.49
Volume 24 ore:
1.70M
Relative Volume:
0.88
Capitalizzazione di mercato:
$863.50M
Reddito:
$187.64M
Utile/perdita netta:
$-95.00M
Rapporto P/E:
-8.8526
EPS:
-0.95
Flusso di cassa netto:
$-69.02M
1 W Prestazione:
-10.63%
1M Prestazione:
+15.21%
6M Prestazione:
+21.36%
1 anno Prestazione:
-39.06%
Intervallo 1D:
$8.21
$8.595
Intervallo di 1 settimana:
$8.21
$9.72
Portata 52W:
$5.635
$13.92
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Nome
Day One Biopharmaceuticals Inc
Settore
Industria
Telefono
650 484-0899
Indirizzo
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
Confronta DAWN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
8.41 | 853.23M | 187.64M | -95.00M | -69.02M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2024-10-09 | Reiterato | Needham | Buy |
| 2024-08-01 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2024-04-24 | Reiterato | Needham | Buy |
| 2023-04-25 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-02-08 | Iniziato | CapitalOne | Overweight |
| 2023-02-03 | Iniziato | Oppenheimer | Perform |
| 2022-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-12-05 | Iniziato | Goldman | Buy |
| 2022-12-01 | Iniziato | BofA Securities | Buy |
Mostra tutto
Day One Biopharmaceuticals Inc Borsa (DAWN) Ultime notizie
How buybacks impact Day One Biopharmaceuticals Inc. stock valueTrade Performance Summary & Verified High Yield Trade Plans - Newser
Day One to buy Mersana Therapeutics for $25/share upfront - MSN
Day One Biopharmaceuticals, Inc. $DAWN Shares Purchased by Geode Capital Management LLC - MarketBeat
Will Day One Biopharmaceuticals Inc. stock deliver shareholder valueJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - Newser
What drives Day One Biopharmaceuticals Inc stock pricePrice Momentum Alerts & Investor Community Interactions - earlytimes.in
(DAWN) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
DAWN CEO moves Day One shares among Bender family trusts - Stock Titan
How Recent Developments Are Shaping the Day One Biopharma Investment Story - Yahoo Finance
HC Wainwright & Co. Reiterates Day One Biopharmaceuticals (DAWN) Buy Recommendation - Nasdaq
DAWN: HC Wainwright & Co. Reaffirms Buy Rating with $25 Target | - GuruFocus
Buy Rating Affirmed for Day One Biopharmaceuticals: Promising FIREFLY-1 Trial Results and Ojemda’s Market Potential - TipRanks
Day One Biopharmaceuticals Announces Three-Year Results from FIREFLY-1 Trial - TradingView
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting - The Manila Times
[8-K] Day One Biopharmaceuticals, Inc. Reports Material Event | DAWN SEC FilingForm 8-K - Stock Titan
Day One Announces Three Year Follow-Up Data From OJEMDA™ - GlobeNewswire
Will Hindalco Industries Limited Stock Benefit From Industry Trends in YEARBearish Engulfing Patterns & Minimize Portfolio Damage with Warnings - earlytimes.in
Is Day One Biopharmaceuticals Inc a good long term investmentRisk Adjusted Returns & High Profit Market Tips - earlytimes.in
Day One Biopharmaceuticals unveils promising Phase 2 trial data - Traders Union
Will Day One Biopharmaceuticals Inc. stock maintain momentum in 2025Trade Analysis Report & Verified Chart Pattern Trade Signals - newser.com
Can Day One Biopharmaceuticals Inc. stock maintain growth trajectoryWeekly Stock Summary & Technical Confirmation Trade Alerts - newser.com
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 161.36%: Here's is How to Trade - MSN
Can Day One Biopharmaceuticals Inc. stock deliver consistent earnings growthJuly 2025 Breakouts & Real-Time Market Trend Scan - newser.com
Will Day One Biopharmaceuticals Inc. stock recover faster than peersAnalyst Upgrade & Safe Entry Zone Tips - newser.com
Day One Biopharmaceuticals, Inc.Common Stock (NQ: DAWN - Markets Financial Content
Day one biopharma gen counsel sells $38k in shares By Investing.com - Investing.com South Africa
Can Day One Biopharmaceuticals Inc. rally from current levelsQuarterly Trade Review & Free Low Drawdown Momentum Trade Ideas - newser.com
Key resistance and support levels for Day One Biopharmaceuticals Inc.Index Update & Safe Swing Trade Setup Alerts - newser.com
Day One Biopharmaceuticals Inc. stock volume spike explainedTrade Signal Summary & Weekly High Conviction Trade Ideas - newser.com
Day one biopharma gen counsel sells $38k in shares - Investing.com
[Form 4] Day One Biopharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Day One Biopharmaceuticals Executives Sell Shares to Cover Tax Liabilities - TradingView
COO York II Acquires 12,813 Of Day One Biopharmaceuticals Inc [DAWN] - TradingView
Day One Biopharmaceuticals CEO Jeremy Bender Sells Shares - TradingView
What Fibonacci levels say about Day One Biopharmaceuticals Inc. reboundTake Profit & Daily Profit Focused Stock Screening - newser.com
Key deals this week: Merck, Day One Biopharmaceutical, ABN AMRO, Revvity, Centerspace and more - MSN
Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Avadel deems Lundbeck offer ‘superior’ to Alkermes’: Deals Report - biocentury.com
Day One Biopharmaceuticals Inc Azioni (DAWN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.10%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):